Tobacco-vax making comes to Texas; India promises crackdown on fakes in New Delhi;

> Count the Texas A&M Health Science Center among those building tobacco-based vaccine manufacturing facilities. Article

> India's chief minister Sheila Dikshit promises an action plan to crack down on spurious drugs in the country's capital, New Delhi. Article

> New Jersey-based Pristine Pharma is moving manufacturing to Massena, NY. Article

> China's drug regulator has granted a manufacturing license to Hebei Aoxing API Pharmaceutical Co., a joint venture of Aoxing Pharma and Macfarlan Smith. Release

> A doubling of production by the biomedical industry led Singapore's manufacturing output to a 31-percent rise over a year earlier. Article

> India's chief minister Sheila Dikshit promises an action plan to crack down on spurious drugs in the country's capital, New Delhi. Article

> World Health Organization officials say fakes and poor storage conditions are driving resistance to malaria drugs. Story

> Aurora Pharmaceutical has completed construction of a 65,000-square-foot facility in Northfield, MN, for manufacturing oral medications, disinfectants and topical preparations for animals. Article

> Armenia is working on a project to stimulate domestic pharmaceutical manufacturing. Story

> Southern Sudan is revamping its pharma supply system with labs and monitoring units to prevent the smuggling of counterfeits. Story

> Sanofi Aventis is using OYSTAR Hüttlin HTG 1800 and HD 600 units in a granulating line for production of acetaminophen tablets. Release

> Datex has announced an IT-support service for users of the FootPrint warehouse management system software. Release

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

AstraZeneca has signed a $750 million deal to produce up to 300 million doses of Oxford University's COVID-19 vaccine by year's end.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot.